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Abstract. The COVID-19 pandemic has brought concurrent challenges. The increased incidence of fake and falsified
product distribution is one of these problems with tremendous impact, especially in low- and middle-income countries.
Up to a tenth of medicines including antibiotics and antimalarial drugs in the African market are considered falsified.
Pandemics make this worse by creating an ecosystem of confusion, distraction, and vulnerability stemming from the
pandemic as health systems become more stressed and the workload of individuals increased. These environments
create opportunities for substandard and falsified medicines to be more easily introduced into the marketplace by
unscrupulous operators. In thiswork,wediscussed someof the challengeswith fake or falsifiedproduct distribution in the
context of COVID-19 and proposed strategies to best manage this problem.
INTRODUCTION
COVID-19 has revealed weaknesses and vulnerabilities in
global and regional health governance,with theproliferation of
“fake health news” and the Surgisphere scandal exacerbating
the dissemination of fake medicines.1–4 These weaknesses
are of particular concern in developing countries with in-
adequate health infrastructures.5,6
Research into finding an effective treatment for COVID-19
hascontinuedunabated.Althoughsomeobservational studies
showed early promise with chloroquine and hydroxy-
chloroquine, subsequent randomized trials revealed the lack
of clinical benefit on these drugs.7,8 The discontinuation of the
major trials on hydroxychloroquine—recovery9 and solid-
arity10—further strengthens the notion that it may not be ef-
fective, especially in severe COVID-19 cases. Subsequently,
randomized trials revealed positive outcomes associatedwith
remdesivir and dexamethasone use in people with severe
COVID-19.11,12 Remdesivir was associated with shorter time
to recovery,11 whereas dexamethasone significantly cut
mortality rates in people on oxygen support.12 COVID-19
management protocols in different jurisdictions are modified
accordingly, although firm evidence is needed to clearly un-
derstand the benefit of these drugs and to whom. On top of
that, accelerated vaccine developments are underway in vari-
ous countries, with 21 of them currently under clinical evalua-
tion and one in phase III testing.
Given the urgency associatedwith finding themagic bullet for
COVID-19, research hasbecome increasingly challenging and is
resulting in self-examination by the scientific community and the
wider public about the governance of fast-tracked research.13
The hype with chloroquine and hydroxychloroquine at the be-
ginning was associated with misinformation14—sometimes in
the form of “fake health news”—and incidents of quarantine-
based supply chain disruption and stockpiling.15
For the Global South, the pandemic exacerbates the
existing proliferation of substandard and falsified medical
products, and these trends are likely to continue as effective
drugs continue to emerge from ongoing trials. The WHO de-
fines substandard products as “authorized medical prod-
ucts that fail to meet quality standards or specifications, or
both” and falsified products as “products that deliberately/
fraudulently misrepresent identity, composition, or source.”16
Considering less than 30%of regulatory agencies in theworld
can ensure the adequacy of medicines and vaccines,17 pan-
demics of COVID-19 proportion would inevitably present
enormous regulatory challenges. Health emergencies can
create an environment of confusion, distraction, and vulner-
ability stemming from the pandemic, as health systems be-
comemore stressed and theworkload of individuals increased.
These environments create opportunities for substandard and
falsified medicines to be more easily introduced into the
marketplace by unscrupulous operators. It is worth noting
that supply chains are fragile even in normal times,18 and
the COVID-19 pandemic made the vulnerabilities with the
supply chains even more noticeable. The supply chain
disruption caused by the reduced production and export of
some medicines owing to closure of China’s active phar-
maceutical ingredient and rawmaterial supply revealed this
vulnerability.19 This has stimulated debate on the need to
diversify the sources of pharmaceutical supply to ensure
continuity of supply across the globe.20 There are ongoing
industry efforts to support initiatives to maximize domestic
productions of raw materials to prevent disruption to the
supply chain in the future.19–21 These problems particularly
need further attention in fragile healthcare systems and are
highly dependent on the import of medicines to cover their
domestic demand.
Falsified medical products may contain no active in-
gredient, the wrong active ingredient, or the wrong amount of
the correct active ingredient.16 The prevalence of falsified
medicines spans from 1% in developed settings to 10% in the
Global South.22,23 Based on more than $4.3 billion worth of
substandard and falsified products seized by border security
agents from 2014 to 2016, over 35% of the products were
antibiotics and 9% were antimalarials.24 Counterfeiters also
target treatments for diabetes, epilepsy, heart diseases, al-
lergy, blood pressure, cancer, and stomach ulcers.25
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Falsified and substandard medicines are deliberately pro-
duced mostly for monetary gain and do not produce the re-
quired therapeutic benefits.16,26–28 Evidence shows that the
use of falsified medicines is associated with serious health
outcomes, includingmortalityboth indevelopinganddeveloped
countries.27 In low- andmiddle-income countries (LMICs) alone,
falsified medicines cost economies up to US$200 billion for
additional care following treatment failure.26,29 Nearly half of the
WHO reports on falsifiedmedical products (42%) originate from
theAfrican region, andmanyare linkedwith antimalarial drugs. In
sub-Saharan Africa, substandard and falsified antimalarials are
estimated to cost US$38.5 million (US$21.4–US$52.4 million)
and 116,000 (64,000–158,000) additional deaths16,29—which
can be prevented.
Falsifiedproducts in thecontext ofCOVID-19.Althougha
true estimate on the impact of falsified medical products
duringCOVID-19 is yet to bemade, the pandemic has fueled a
global surge in the production and distribution of falsified
medicines and medical supplies25—resulting in a multifold
global crisis. This is evident from recent operations by The
International Criminal Police Organization that captured mil-
lions of units of counterfeit pharmaceuticals (antiviral medi-
cations, antimalarial chloroquine, vitamin C, painkillers, and
antibiotics), coupled with several reports on the counterfeit
medical supplies (mostly surgical masks and coronavirus
testing kits) fromaround theglobe.Similarly, inAfrica, theearly
days of the pandemic have seen a spike in the demand for
chloroquine and hydroxychloroquine that subsequently led to
a surge in their falsified version.30 The WHO global surveil-
lance and monitoring system on substandard and falsified
medical products received nine reports of confirmed falsified
chloroquine products from three countries—Cameroon,
Democratic Republic of Congo, and Niger betweenMarch 31,
2020 and April 2, 2020.31 This is a worrisome development for
a continent with a long-standing problem of falsified antima-
larial drugs.32 Looking at the trends of a surge in falsified
products and in the absence of proper regulation, drugs such
as dexamethasone may have a similar fate. Therefore, regu-
latory agencies should have additional oversight on the dis-
tribution of products containing this drug to ensure their
quality, particularly in settings where product regulation is
weak. The trend is also likely to bemuch higher this year as the
demand for important drugs exceeds the supply, following
COVID-19–led lockdowns in India and China (two largest
producers of medical products).8,30
African nations are largely spending their scarce resources
onCOVID-19 containmentmeasures, aiming to prevent large-
scale disease dissemination that can lead to huge health,
social, and economic crises. This will undoubtedly leave them
with limited capacity to tackle other parallel emergencies.
Falsifiedmedicines tend to emergewhen access tomedicines
is constrained, when the pharmaceutical governance is weak,
where there is limited technical capacity to monitor products
throughout the supply chain, and when there is lack of ade-
quate financial and political commitments.33 These standards
come under the purview of the national regulatory system. A
looming recession on the horizon is also likely to stimulate
social tolerance for substandard and falsified medical prod-
ucts. Strong regulatory frameworks are, therefore, essential in
enabling regulatory authorities to effectively combat the dis-
tribution of falsified medicines. Corrupt and under-resourced
systems, coupled with limited capacity for oversight, allow
falsifiedmedicine to easily reach the end user.32 High-income
countries have a strict regulatory framework, technological
means, and financial resources to detect and limit the distri-
bution of falsified and counterfeited products. The penetration
of counterfeit products is generally higher in LMIC settings.
There is a risk that when the COVID-19 pandemic further
spreads in LMICs, there will be an increased potential for the
distribution of falsified and counterfeit medicines, something
the international community needs to be alert to and work
against.
Ongoing efforts to tackle distribution of falsified products.
Given the complexity of the pharmaceutical distribution and
supply chain, vulnerabilities could occur at any stage across
the supply chain, endangering patients around the world.34
Building collaborations across countries and private and
public agencies is required to strengthen the regulatory foot-
print at national and international levels. The U.S. Food and
Drug Administration and the European Medicines Agency are
trialing to implement various technologies to track the steps
involved in the supply chain. In Africa, a health information
technology/big data startup RxAll has come up with a hand-
held scanner, which collects the spectral signature of a drug
and then compares it with a cloud-based database and sends
information to an application on the phone. Although field
detection technologies could play a role in intercepting sub-
standard and falsified products, their cost feasibility andwhen
to effectively use them across the supply chain continuum
remain to be understood.35,36 Also, this seems to be a pallia-
tive approach to a multifactorial systemic problem.
There are some global efforts to improve access and quality
of medicines. The United States Agency for International De-
velopment (USAID) Global Health Supply Chain Program is
exploring innovations based on prior experiences to devise
more efficient supply chains aiming to implement global
supply chain standards (GS1) for improved cost, efficiency,
and availability of health commodities worldwide.37 Further-
more, some programs specifically aim to strengthen regula-
tory agencies in LMICs with the ultimate goal to ensure
sustainable access to appropriate, safe, affordable, and
quality-assured medicines.38,39 This also includes supply
chain strengthening activities undertaken by USAID, UNICEF,
the United Nations Population Fund, the Global Fund, Bill &
Melinda Gates Foundation, and others that focus on sup-
porting the end to end product traceability supported by the
use of novel technologies. However, recent attempts to halt
fundingarrangements for theWHOcouldbeaserious threat to
global health security, especially in the middle of a cata-
strophic global pandemic.
CONCLUSION
In summary, the availability and distribution of falsified
products is an age-old problem, with higher penetration in
LMICs, a situation that is likely to get worse as disruptions
place greater stresses on regulatory and supply chain
processes. In the age of COVID-19, there is an ongoing need
to ensure adequate supplies of medicines and medical
equipment, not only for meeting the needs of the pandemic
but also for other health needs. In meeting these needs,
governments, pharmaceutical regulatory agencies, and as-
sociate supply chains must have practical and financially
supported strategies to ensure quality-assuredmedicines are
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madeavailable for the determined need.More importantly, it is
imperative medicines regulatory authorities and relevant
stakeholders implement robust authentication and pro-
curement processes to ensure quality medicines supply.40 In
linewith this, we propose the following set of strategies can be
cascaded to relevant stakeholders (Table 1) to ensure the
availability of quality medicines during the time of COVID-19
and beyond.
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